Mycobacterium tuberculosis sterilizing activity of faropenem, pyrazinamide and linezolid combination and failure to shorten the therapy duration

Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions

(2020) Alvaro A. Ordonez et al.   NATURE MEDICINE

Treatment of Highly Drug-Resistant Pulmonary Tuberculosis

(2020) Francesca Conradie et al.   NEW ENGLAND JOURNAL OF MEDICINE

Drug Penetration Gradients Associated with Acquired Drug Resistance in Tuberculosis Patients

(2018) Keertan Dheda et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

A comparison of linezolid lung tissue concentrations among patients with drug-resistant tuberculosis

(2018) Russell R. Kempker et al.   EUROPEAN RESPIRATORY JOURNAL

Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation

(2018) James Millard et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pan-tuberculosis regimens: an argument against

(2018) Keertan Dheda et al.   Lancet Respiratory Medicine

Pan-tuberculosis regimens: an argument for

(2018) Robert S Wallis et al.   Lancet Respiratory Medicine

OUP accepted manuscript

(2018)   CLINICAL INFECTIOUS DISEASES

Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis

(2017) Devyani Deshpande et al.   Science Advances

Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks

(2016) Shashikant Srivastava et al.   CLINICAL INFECTIOUS DISEASES

A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way

(2016) Devyani Deshpande et al.   CLINICAL INFECTIOUS DISEASES

Linezolid for Infants and Toddlers With Disseminated Tuberculosis: First Steps

(2016) Devyani Deshpande et al.   CLINICAL INFECTIOUS DISEASES

Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo

(2016) Devyani Deshpande et al.   CLINICAL INFECTIOUS DISEASES

Serum Drug Concentrations Predictive of Pulmonary Tuberculosis Outcomes

(2013) J. G. Pasipanodya et al.   JOURNAL OF INFECTIOUS DISEASES

In Vitro and In Vivo Modeling of Tuberculosis Drugs and its Impact on Optimization of Doses and Regimens

(2012) Shashikant Srivastava et al.   CURRENT PHARMACEUTICAL DESIGN

Pharmacokinetic Mismatch Does Not Lead to Emergence of Isoniazid- or Rifampin-Resistant Mycobacterium tuberculosis but to Better Antimicrobial Effect: a New Paradigm for Antituberculosis Drug Scheduling

(2011) Shashikant Srivastava et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Multidrug-Resistant Tuberculosis Not Due to Noncompliance but to Between-Patient Pharmacokinetic Variability

(2011) Shashikant Srivastava et al.   JOURNAL OF INFECTIOUS DISEASES

Pharmacokinetics-Pharmacodynamics of Pyrazinamide in a Novel In Vitro Model of Tuberculosis for Sterilizing Effect: a Paradigm for Faster Assessment of New Antituberculosis Drugs

(2009) T. Gumbo et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Faropenem Medoxomil

(2007) Jacob P Gettig et al.   ANNALS OF PHARMACOTHERAPY